Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032300 | 0.94 | MEN1 (0.57) | NAMPTCA1CA2L3MBTL1HDAC1 | |
| SCHEMBL10165179 | 0.92 | NAMPT (0.56) | NAMPTCA1CA2L3MBTL1HDAC1 | |
| SCHEMBL3007876 | 0.92 | NAMPT (0.49) | NAMPTCA1CA2L3MBTL1LOXL2 | |
| SCHEMBL25440112 | 0.91 | NAMPT (0.51) | NAMPTCA1CA2L3MBTL1LOXL2 | |
| SCHEMBL24891764 | 0.89 | NAMPT (0.65) | NAMPTCA1CA2HDAC1SMN1; SMN2 | |
| SCHEMBL3180689 | 0.88 | L3MBTL1 (0.61) | NAMPTCA1CA2L3MBTL1HDAC1 | |
| SCHEMBL8337876 | 0.88 | NAMPT (0.53) | NAMPTCA1CA2L3MBTL1HDAC1 | |
| SCHEMBL3905352 | 0.87 | HTT (0.59) | NAMPTCA1CA2L3MBTL1HDAC1 | |
| SCHEMBL5544971 | 0.86 | NAMPT (0.46) | NAMPTL3MBTL1HDAC1ALDH1A1 | |
| SCHEMBL8127981 | 0.86 | EPHX2 (0.59) | NAMPTCA1CA2L3MBTL1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025085489-A1 | GSPT1-DEGRADING COMPOUNDS, ANTI-CD33 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250092012-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2025-03-20 | — | — | US | disclosed |
| EP-4508044-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12187699-B2 | GSPT1 compounds and methods of use of the novel compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-07 | — | — | US | disclosed |
| CN-119013266-A | Novel GSPT compounds and methods of use of novel compounds | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2023201282-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023201282-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-19 | — | — | WO | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0934065-A4 | PHARMACEUTICAL COMPOUNDS | LILLY CO ELI (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0934065-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998008505-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | NAMPT 2536/4885CA1 4318/4885CA2 4400/4885 |
| US-20250092012-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | GSPT1, GSS, GSPT2 | NAMPT 29/4885CA1 1202/4885CA2 910/4885 |
| US-12187699-B2 | GSPT1 compounds and methods of use of the novel compounds | GSPT1, GSS, GSPT2 | NAMPT 29/4885CA1 1202/4885CA2 910/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | NAMPT 2566/4885CA1 941/4885CA2 2484/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | NAMPT 538/4885CA1 1012/4885CA2 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.